ALNA Allena Pharmaceuticals Inc

Price (delayed)

$0.124

Market cap

$13.36M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.65

Enterprise value

$9.81M

Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena's ...

Highlights
Allena Pharmaceuticals's debt has decreased by 49% YoY and by 48% from the previous quarter
The EPS is up by 30% year-on-year and by 10% since the previous quarter
ALNA's quick ratio has dropped by 84% year-on-year and by 54% since the previous quarter
Allena Pharmaceuticals's equity has plunged by 51% YoY and by 38% from the previous quarter

Key stats

What are the main financial stats of ALNA
Market
Shares outstanding
107.73M
Market cap
$13.36M
Enterprise value
$9.81M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.96
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$47.85M
EBITDA
-$47.04M
Free cash flow
-$55.92M
Per share
EPS
-$0.65
Free cash flow per share
-$0.63
Book value per share
$0.13
Revenue per share
$0
TBVPS
$0.24
Balance sheet
Total assets
$21.73M
Total liabilities
$10.12M
Debt
$5.35M
Equity
$11.62M
Working capital
$10.08M
Liquidity
Debt to equity
0.46
Current ratio
2
Quick ratio
0.88
Net debt/EBITDA
0.08
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-149.5%
Return on equity
-284%
Return on invested capital
-950.7%
Return on capital employed
-411.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALNA stock price

How has the Allena Pharmaceuticals stock price performed over time
Intraday
-6.56%
1 week
3.25%
1 month
11.61%
1 year
-90.75%
YTD
-79.07%
QTD
-46.37%

Financial performance

How have Allena Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$47.8M
Net income
-$48.84M
Gross margin
N/A
Net margin
N/A
The operating income has contracted by 33% YoY
ALNA's net income is down by 32% year-on-year

Growth

What is Allena Pharmaceuticals's growth rate over time

Valuation

What is Allena Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.96
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 30% year-on-year and by 10% since the previous quarter
ALNA's price to book (P/B) is 71% lower than its last 4 quarters average of 3.3 and 69% lower than its 5-year quarterly average of 3.1
Allena Pharmaceuticals's equity has plunged by 51% YoY and by 38% from the previous quarter

Efficiency

How efficient is Allena Pharmaceuticals business performance
ALNA's ROIC has shrunk by 86% YoY
The ROE has plunged by 59% YoY and by 18% from the previous quarter
Allena Pharmaceuticals's return on assets has decreased by 42% YoY and by 15% QoQ

Dividends

What is ALNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALNA.

Financial health

How did Allena Pharmaceuticals financials performed over time
Allena Pharmaceuticals's total assets is 115% higher than its total liabilities
ALNA's quick ratio has dropped by 84% year-on-year and by 54% since the previous quarter
The current ratio has plunged by 65% YoY and by 5% from the previous quarter
Allena Pharmaceuticals's debt is 54% less than its equity
Allena Pharmaceuticals's equity has plunged by 51% YoY and by 38% from the previous quarter
Allena Pharmaceuticals's debt has decreased by 49% YoY and by 48% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.